L 649923

Drug Profile

L 649923

Latest Information Update: 24 Mar 2010

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antiallergics; Antiasthmatics; Antiulcers
  • Mechanism of Action Leukotriene receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Peptic ulcer

Most Recent Events

  • 03 Nov 1998 No-Development-Reported for Peptic ulcer in United Kingdom (PO)
  • 21 Oct 1996 L 649923 is being investigated for use in Peptic Ulcer Disease
  • 21 Oct 1996 Preclinical development for Peptic ulcer in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top